NKG2A targeting with monalizumab (a humanized anti-NKG2A antibody) has been shown to enhance the anti-tumor immunity mediated by NK and CD8+ T cells when used as a single agent or in combination with other therapeutic antibodies such as durvalumab (blocking PD-L1), or cetuximab (directed against the epidermal growth factor receptor, EGFR) (99, 100). Here, EGFR is linked to neoplasm.